Comment on

• Factor VIII products and inhibitor development in severe hemophilia A.

  Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Gouw SC, et al. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024. N Engl J Med. 2013. PMID: 23323899
• The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.

  Kessler CM, Iorio A. Kessler CM, et al. Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12. Haemophilia. 2013. PMID: 23577743 No abstract available.
• Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.

  van der Bom JG, Gouw SC, Rosendaal FR. van der Bom JG, et al. Haemophilia. 2014 Mar;20(2):e171-4. doi: 10.1111/hae.12342. Epub 2013 Dec 26. Haemophilia. 2014. PMID: 24372628 No abstract available.